ESMO-IASLC BEST ABSTRACTS: THE EVOLVING LANDSCAPE OF IMMUNOTHERAPY

Monotherapy with checkpoint inhibitors: Any chance for a long term plateau? (Including discussion of 137O)

M. Reck